ASH 2020: Ruxolitinib an Effective Treatment for Refractory Acute Graft Versus Host Disease
Patients who did not respond to corticosteroids did better with ruxolitinib than best available therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.